Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.45−0.03 (-5.40%)
Close on Nov 16, 2026Market cap $124.31MP/E –Yield –
Akebia Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Akebia Therapeutics's total assets was $349.66M at Jun 30, 2026. For fiscal 2025 it was $376.57M, up 70.6% from the year before. Over ten years it grew 10.2% a year on average. The highest annual figure on record is $996.54M in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $376.57M | +70.6% |
| FY2024 | Dec 31, 2024 | $220.67M | -8.7% |
| FY2023 | Dec 31, 2023 | $241.70M | -32.1% |
| FY2022 | Dec 31, 2022 | $356.05M | -32.7% |
| FY2021 | Dec 31, 2021 | $529.35M | -17.8% |
| FY2020 | Dec 31, 2020 | $644.14M | -16.5% |
| FY2019 | Dec 31, 2019 | $771.20M | -22.6% |
| FY2018 | Dec 31, 2018 | $996.54M | +173.6% |
| FY2017 | Dec 31, 2017 | $364.25M | +21.3% |
| FY2016 | Dec 31, 2016 | $300.22M | +110.0% |
| FY2015 | Dec 31, 2015 | $142.94M | +28.8% |
| FY2014 | Dec 31, 2014 | $111.00M | +220.2% |
| FY2013 | Dec 31, 2013 | $34.67M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $349.66M | +1.2% |
| Q1 FY2026 | Mar 31, 2026 | $362.52M | +16.9% |
| Q4 FY2025 | Dec 31, 2025 | $376.57M | +70.6% |
| Q3 FY2025 | Sep 30, 2025 | $364.15M | +75.8% |
| Q2 FY2025 | Jun 30, 2025 | $345.60M | +56.9% |
| Q1 FY2025 | Mar 31, 2025 | $310.19M | +37.6% |
| Q4 FY2024 | Dec 31, 2024 | $220.67M | -8.7% |
| Q3 FY2024 | Sep 30, 2024 | $207.14M | -11.9% |
| Q2 FY2024 | Jun 30, 2024 | $220.20M | -13.2% |
| Q1 FY2024 | Mar 31, 2024 | $225.48M | -19.7% |
| Q4 FY2023 | Dec 31, 2023 | $241.70M | -32.1% |
| Q3 FY2023 | Sep 30, 2023 | $235.00M | -47.1% |
| Q2 FY2023 | Jun 30, 2023 | $253.71M | -52.1% |
| Q1 FY2023 | Mar 31, 2023 | $280.93M | -48.1% |
| Q4 FY2022 | Dec 31, 2022 | $356.05M | -32.7% |
| Q3 FY2022 | Sep 30, 2022 | $444.25M | -26.2% |
| Q2 FY2022 | Jun 30, 2022 | $529.88M | -13.4% |
| Q1 FY2022 | Mar 31, 2022 | $541.80M | -13.8% |
| Q4 FY2021 | Dec 31, 2021 | $529.35M | -17.8% |
| Q3 FY2021 | Sep 30, 2021 | $602.27M | -10.9% |
| Q2 FY2021 | Jun 30, 2021 | $611.86M | -17.9% |
| Q1 FY2021 | Mar 31, 2021 | $628.70M | -20.2% |
| Q4 FY2020 | Dec 31, 2020 | $644.14M | -16.5% |
| Q3 FY2020 | Sep 30, 2020 | $676.14M | -15.0% |
| Q2 FY2020 | Jun 30, 2020 | $745.17M | -9.5% |
| Q1 FY2020 | Mar 31, 2020 | $787.72M | -11.6% |
| Q4 FY2019 | Dec 31, 2019 | $771.20M | -22.6% |
| Q3 FY2019 | Sep 30, 2019 | $795.22M | +96.9% |
| Q2 FY2019 | Jun 30, 2019 | $823.53M | +99.0% |
| Q1 FY2019 | Mar 31, 2019 | $890.79M | +101.2% |
| Q4 FY2018 | Dec 31, 2018 | $996.54M | +173.6% |
| Q3 FY2018 | Sep 30, 2018 | $403.83M | +19.3% |
| Q2 FY2018 | Jun 30, 2018 | $413.78M | +22.8% |
| Q1 FY2018 | Mar 31, 2018 | $442.71M | +70.8% |
| Q4 FY2017 | Dec 31, 2017 | $364.25M | +21.3% |
| Q3 FY2017 | Sep 30, 2017 | $338.59M | +100.2% |
| Q2 FY2017 | Jun 30, 2017 | $336.82M | – |
| Q1 FY2017 | Mar 31, 2017 | $259.26M | – |
| Q4 FY2016 | Dec 31, 2016 | $300.22M | – |
| Q3 FY2016 | Sep 30, 2016 | $169.12M | – |
See a number that looks wrong?